Aktie A3DWU1 ADHERA THERAPEUTICS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Adhera Therapeutics, Inc.

Aktien

A3DWU1

US00687E4061

ATRX

Markt geschlossen - OTC Markets
Andere Börsenplätze
 19:00:56 17.05.2024 		% 5 Tage % 1. Jan.
0.006 USD -25.93% Intraday Chart für Adhera Therapeutics, Inc. +15.38% -80.00%
18.01. Adhera Therapeutics, Inc. Erhält schriftliche Mitteilung von Melior Pharmaceuticals II, LLC über die Beendigung des Lizenzvertrags CI
16.01. Adhera Therapeutics, Inc. gibt den Rücktritt von Zahed Subhan als Chief Executive Officer bekannt CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Adhera Therapeutics, Inc. Receives Written Notice from Melior Pharmaceuticals II, LLC of Election to Terminate the License Agreement
Adhera Therapeutics, Inc. Announces the Resignation of Zahed Subhan as Chief Executive Officer
Adhera Therapeutics, Inc. Announces Board Resignations
Adhera Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
BigTime Penny Stocks: OTCQB Venture Market Watchlist (WOEN, ATRX, EDXC, CBDS, OMTK)
Adhera Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Thinking about buying stock in Vistagen Therapeutics, Origin Materials, MedAvail Holdings, United States Lime & Minerals, or Adhera Therapeutics?
Adhera Therapeutics, Inc. announced that it has received $0.105 million in funding
Adhera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Adhera Therapeutics, Inc. announced that it has received $0.1 million in funding
Adhera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Adhera Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt
Adhera Therapeutics, Inc. announced that it has received $0.214285 million in funding
Adhera Therapeutics, Inc. announced that it has received $0.364285 million in funding
Adhera Therapeutics to Collaborate with Alberta Diabetes Institute, University of Alberta to Initiate Clinical Trial of MLR-1023 in Type 1 Diabetes
Adhera Therapeutics, Inc. announced that it has received $0.1 million in funding
Adhera Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Adhera Therapeutics Announces CEO, Senior Management Changes, Plans for NASDAQ Uplist
Adhera Therapeutics, Inc. Elects Zahed Subhan as Chairman of the Board
ADHERA THERAPEUTICS, INC. : Change in Directors or Principal Officers, Regulation FD Disclosure (form 8-K)
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3DWU1 Aktie
  4. Nachrichten Adhera Therapeutics, Inc.
  5. Andere Sprachen